GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2009

Bayer Decides to Investigate Compugen’s Newly Discover Cancer Targets

  • Bayer Schering Pharma has inked a deal to evaluate a Compugen-discovered tumor target and its splice variants. Following an initial six-month joint research stage, the agreement provides Bayer with an option for an exclusive, worldwide, royalty-bearing license for development of mAbs and other therapeutic agents addressing these target molecules.

    The existence of the target and its splice variants was initially predicted in silico by Compugen through the use of its Monoclonal Antibody Targets Discovery platform. The newly discovered target and its splice variants are variants of a known cancer target for which therapeutic agents are currently in preclinical development by other organizations. Like the known cancer target, this protein molecule and its variants are all trans-membrane proteins. However, each of the Compugen molecules has a unique sequence at the extracellular domain of the protein that enables the development of mAbs specific to each of the respective splice variants.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »